Bicara Therapeutics Inc. (BCAX) Stock Price & Analysis

Bicara Therapeutics Inc. (BCAX) closed at USD 9.76 on Wednesday, October 28, 2026, down 44.16% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 17.48; the Oct 28, 2026 session ranged USD 8.9–17.57 on volume of 15,376,724 shares. Market capitalization is $645.85M, with a 52-week range of USD 8.9–30.99 (NGM). Source: Nexqual, retrieved October 28, 2026 at 23:29 UTC.

Also available as compact Markdown for AI agents: nexqual.com/BCAX.md

Key facts (BCAX)

• Analysts: Buy (mean 1.86 on a 1–5 scale) (14 analysts), mean target USD 35.67 (range 20–45).
• Total return with dividends: 1Y -38.5% vs S&P 500 +13.6%; 5Y -58.3% vs S&P 500 +79.8%.
• Next earnings: 2026-11-10, EPS estimate USD -0.82, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BCAX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (BCAX)

P/B 1.4x · FCF yield -20.94% · Earnings yield -28.70%

Analysts (BCAX)

Consensus Buy (mean 1.86 on a 1–5 scale), 14 analysts; mean target USD 35.67 (low 20, high 45).

Rating changes, last 120 days:

Total return (dividends reinvested) (BCAX)

BCAX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

BCAX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

BCAX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 30, 2026.

BCAX company outlook (results filed Aug 11, 2026)

• “Cohlhepp's direction as the company prepares for the potential commercialization of ficerafusp alfa in first-line (1L) recurrent or metastatic (R/M) human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), with topline data from an interim analysis of the FORTIFI-HN01 pivotal trial expected in mid-2027. • Tanya Green, Chief Development Officer, will succeed Dr.”
• “The company expects to have results from this study by the time of a potential U.S. accelerated approval in 1L R/M HPV-negative HNSCC. • Presented extended follow-up data out to three years from the Phase 1/1b study of ficerafusp alfa in combination with pembrolizumab in 1L R/M HPV-negative HNSCC at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.”
• “Key Anticipated Upcoming Milestones HNSCC • Continued to enroll Phase 3 of the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC and expect to be substantially enrolled by the end of the year to enable topline results from an interim analysis in mid-2027.”
• “Based on its current operating and development plans, the company expects that its existing cash, cash equivalents and marketable securities will fund operations into the first half of 2029. • Research and Development Expenses: Research and development expenses were $45.8 million for the second quarter of 2026 as compared to $24.8 million for the second quarter of 2025.”

Quoted word-for-word from the SEC 8-K results press release.

BCAX analyst estimates and revisions

BCAX options: expected move

Options price a move of about ±41.6% (±$3.95) by Nov 20, 2026, which includes earnings on Nov 10, 2026. Over the last 8 reports the stock moved ±5.6% on average.

30-day implied volatility 99.4% vs 174.6% realized over the last 30 trading days. Put/call ratio (volume) 0.03. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 23:29 UTC)

Technical Analysis (BCAX)

Nexqual's technical model rates BCAX "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of October 28, 2026 at 23:29 UTC.

Analyst Ratings (BCAX)

Wall Street analysts rate BCAX "Buy" based on 14 analysts, with a mean price target of USD 35.67 (range USD 20–45), per Nexqual as of October 28, 2026 at 23:29 UTC.

Earnings (BCAX)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 23:29 UTC.

Financials & Fundamentals (BCAX)

Source: Nexqual, October 28, 2026 at 23:29 UTC.

Financial Health Score (BCAX)

Nexqual rates Bicara Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of October 28, 2026 at 23:29 UTC.

Ownership (BCAX)

Source: Nexqual, October 28, 2026 at 23:29 UTC.

Leadership (BCAX)

Bicara Therapeutics Inc. is led by Claire Mazumdar Clemon, CEO & Director, per Nexqual as of October 28, 2026 at 23:29 UTC.

Major Backers & Investors (BCAX)

Notable institutional backers of Bicara Therapeutics Inc. include RA Capital Management, L.P., T. Rowe Price, Siren, L.L.C., according to Nexqual as of October 28, 2026 at 23:29 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 23:29 UTC.

From Bicara Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• We seek to protect the intellectual property and proprietary technology that we consider important to our business, including by pursuing patent applications that cover our product candidates and methods of using the same, as well as any other relevant inventions and improvements that we believe to be commercially important to the development of our business.
• We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.
• As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted.
• We have built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.

Partnerships

• In connection with the Biocon Agreement, we paid INR 550 million as consideration for the license grant.

Legal & Regulatory Risks (Item 1A, quoted)

• We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed.
• We intend to develop our product candidates in part in combination with other therapies and may develop our future product candidates in combination with other therapies, which exposes us to additional regulatory risks.
• We may also evaluate ficerafusp alfa or any future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA, Health Canada, the EMA or comparable foreign regulatory authorities.
• The FDA and other regulatory authorities' policies may change, and additional government regulations may be enacted that could prevent, limit or delay marketing approval of a product.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 23:29 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt